"Iambic Therapeutics Raises $50M for Pipeline Expansion and Development"

Iambic Therapeutics raises $50M in Series B Extension Funding

Iambic Therapeutics (Linkedin), a leading biotechnology research company based in the United States, has secured $50 million in Series B extension funding. With a focus on innovative drug discovery solutions and therapies, Iambic Therapeutics aims to address difficult-to-treat biological targets, particularly in the field of oncology and solid tumor treatment.

Funding Amount: $50 million

Industry: Biotechnology Research

Employee Count: 51-200

CEO: Tom Miller (CEO Linkedin)

What Iambic Therapeutics needs to buy: Iambic Therapeutics is seeking research and development partnerships, clinical trial support, and regulatory and compliance expertise. Companies specializing in drug discovery, clinical trial services, and regulatory consulting can collaborate with Iambic Therapeutics to advance their pipeline programs and ensure successful development and commercialization of their therapies.